Health Matters: The financial toll of ALS - Global News
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
Wellness Wednesday: Pressures of youth sports
Greater Vancouver businesses share economic concerns in GVBOT survey
This article is an excerpt. To read the full content, visit the original source. Global News
Related articles
Nasal delivery of ALS treatment in tiny cell-made sacs delays disease onset in mice - Medical Xpress
Credit: Journal of Extracellular Vesicles (2026). One of the great challenges in treating diseases like amyotrophic lateral sclerosis (ALS) is not necessarily finding a promising drug. It is getting the drug to the right place. New research from the University of Georgia's Regenerative Bioscience Center (RBC) is revealing how tiny, naturally produced carriers could help deliver medicines to the cells that need them most.
Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group
Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.
European Medical Journal | HIV linked to early signs of heart dysfunction - European AIDS Treatment Group
European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.
0 comments
No comments yet. Be the first to share your thoughts!